Skip to main content

Table 1 Baseline clinical characteristics

From: Association between cardiac autonomic function and physical activity in patients at high risk of sudden cardiac death: a cohort study

Parameters

Total (n = 342)

Tertile 1 (n = 114)

Tertile 2 (n = 114)

Tertile 3 (n = 114)

P value

Home monitoring data

 Baseline PA, %

10.80 ± 5.35

5.18 ± 2.01

10.30 ± 1.48

16.93 ± 3.19

–

 Baseline HRV, ms

71.14 ± 27.63

62.40 ± 25.43

72.23 ± 26.87

78.80 ± 28.85

–

Demographics

 Gender, male

78.4% (268)

76.3% (87)

74.6% (85)

84.2% (96)

P = 0.169

 Age at implantation, years

62.37 ± 13.48

66.32 ± 13.66

63.26 ± 13.07

57.52 ± 12.26

P < 0.001

 BMI, Kg/m2

23.56 ± 2.87

23.62 ± 2.85

23.53 ± 3.26

23.72 ± 2.45

P = 0.890

CRT-D implantation

53.8% (184)

51.8% (59)

57.9% (66)

51.8% (59)

P = 0.562

 NYHA, Class III-IV

61.4% (210)

67.5% (77)

61.4% (70)

55.3% (63)

P = 0.163

Echocardiography

 LVEF, %

39.13 ± 14.43

38.64 ± 14.61

39.48 ± 14.20

39.29 ± 14.60

P = 0.900

 LVEDD, mm

62.38 ± 13.20

60.17 ± 11.36

62.76 ± 13.69

64.23 ± 14.18

P = 0.066

Comorbidities

 Hypertension

35.1% (120)

39.5% (45)

43.0% (49)

22.8% (26)

P = 0.003

 DM

14.6% (50)

17.5% (20)

14.0% (16)

12.3% (14)

P = 0.519

 Stroke

2.6% (9)

7.0% (8)

0.9% (1)

0.0% (0)

P = 0.001

 DCM

29.8% (102)

28.9% (33)

29.8% (34)

30.7% (35)

P = 0.959

 HCM

3.8% (13)

0.9% (1)

5.3% (6)

5.3% (6)

P = 0.081

 ICM

39.8% (136)

47.7% (54)

42.1% (48)

29.8% (34)

P = 0.021

 Valve disease

2.3% (8)

3.5% (4)

1.8% (2)

1.8% (2)

P = 0.671

 Prior MI

14.0% (48)

20.2% (23)

12.3% (14)

9.6% (11)

P = 0.059

 PCI

11.7% (40)

21.1% (24)

9.6% (11)

4.4% (5)

P < 0.001

 CABG

1.8% (6)

3.5% (4)

0.0% (0)

1.8% (2)

P = 0.060

 Prior paroxysmal AF

7.6% (26)

9.6% (11)

7.0% (8)

6.1% (7)

P = 0.582

 LQTS

1.5% (5)

0.9% (1)

1.8% (2)

1.8% (2)

P = 0.801

 Pre-implant syncope

15.8% (54)

19.3% (22)

9.6% (11)

18.4% (21)

P = 0.087

Medication

 ACEIs/ARBs

41.5% (142)

43.0% (49)

43.9% (50)

37.7% (43)

P = 0.596

 Diuretics

33.0% (113)

39.5% (45)

31.6% (36)

28.1% (32)

P = 0.172

 Aldosterone antagonists

45.0% (154)

51.8% (59)

41.2% (47)

42.1% (48)

P = 0.208

 CCBs

10.2% (35)

2.0% (7)

5.6% (19)

2.6% (9)

P = 0.019

 Statins

22.8% (78)

24.6% (28)

28.1% (32)

15.8% (18)

P = 0.075

 Beta-blockers

57.6% (197)

57.0% (65)

57.9% (66)

57.9% (66)

P = 0.988

 Amiodarone

28.1% (96)

27.2% (31)

23.7% (27)

33.3% (38)

P = 0.260

 Antiplatelets

21.6% (74)

27.2% (31)

22.8% (26)

14.9% (17)

P = 0.074

  1. ACEIs angiotensin-converting enzyme inhibitors, AF atrial fibrillation, ARBs angiotensin receptor blockers, BMI body mass index, CABG coronary artery bypass grafting, CCB calcium channel blockers, CRT-D cardiac resynchronization therapy with defibrillation, DCM dilated cardiomyopathy, DM diabetes mellitus, HCM hypertrophic cardiomyopathy, HRV heart rate variability, ICM ischemic cardiomyopathy, LQTS long QT syndrome, LVEF left ventricular ejection fraction, LVEDD left ventricular end-diastolic dimension, MI myocardial infarction, PA physical activity, PCI percutaneous coronary intervention
Back to article page

International Journal of Behavioral Nutrition and Physical Activity

ISSN: 1479-5868

Contact us